Artivion (NYSE:AORT) Rating Lowered to “Buy” at Wall Street Zen

by · The Cerbat Gem

Artivion (NYSE:AORT – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Several other analysts have also weighed in on AORT. JMP Securities lifted their price objective on shares of Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Needham & Company LLC upped their price objective on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a report on Friday, November 7th. Citigroup restated an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Finally, Canaccord Genuity Group boosted their target price on Artivion from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Artivion currently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Get Our Latest Analysis on AORT

Artivion Stock Down 0.7%

Shares of Artivion stock opened at $45.16 on Friday. Artivion has a one year low of $21.97 and a one year high of $48.04. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. The stock’s 50-day moving average is $44.34 and its 200 day moving average is $38.78. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of -188.17 and a beta of 1.60.

Artivion (NYSE:AORT – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The business had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion’s revenue was up 18.9% on a year-over-year basis. Equities research analysts anticipate that Artivion will post 0.37 EPS for the current year.

Insider Activity at Artivion

In other Artivion news, SVP Jean F. Holloway sold 7,315 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $45.30, for a total transaction of $331,369.50. Following the completion of the sale, the senior vice president directly owned 156,093 shares of the company’s stock, valued at approximately $7,071,012.90. The trade was a 4.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth A. Hoff sold 4,200 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $45.10, for a total value of $189,420.00. Following the completion of the sale, the director directly owned 27,189 shares of the company’s stock, valued at approximately $1,226,223.90. This trade represents a 13.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 234,511 shares of company stock valued at $10,612,452 over the last quarter. 8.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Artivion

Several institutional investors have recently bought and sold shares of the stock. Verition Fund Management LLC raised its position in Artivion by 1.6% in the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after buying an additional 274 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of Artivion by 1.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock worth $985,000 after acquiring an additional 414 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Artivion by 6.2% in the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after purchasing an additional 477 shares during the last quarter. Van ECK Associates Corp lifted its position in shares of Artivion by 19.0% during the third quarter. Van ECK Associates Corp now owns 3,176 shares of the company’s stock valued at $134,000 after purchasing an additional 506 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of Artivion by 5.8% during the third quarter. Oregon Public Employees Retirement Fund now owns 9,329 shares of the company’s stock valued at $395,000 after purchasing an additional 510 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Featured Stories